Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
 9 Months Ended
Jun. 30, 2014
Jun. 30, 2013
OPERATING ACTIVITIES    
Net loss $ (6,042,265) $ (3,849,041)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services   214,500
Fair value of warrants issued for services 1,078,669 260,942
Fair value of employee stock options 1,119,724 444,162
Loss on derivative liability   1,117,642
Depreciation 11,750 7,092
Amortization of patent costs 148,969 58,395
Changes in operating assets and liabilities    
Prepaid expenses and deposits 49,924 69,837
Other receivables and other current assets (28,519)  
Accounts payable and accrued expenses (120,730) (88,782)
Net Cash Used in Operating Activities (3,782,478) (1,765,253)
INVESTING ACTIVITIES    
Cash paid for acquisition of SKS Ocular's assets (3,500,000)  
Net Cash Used in Investing Activities (3,500,000)  
FINANCING ACTIVITIES    
Proceeds from the sale of common stock 16,876,000  
Proceeds from warrants exercised for cash 260,752 5,224,672
Repayments of short-term notes payable (99,134) (43,237)
Net Cash Provided by Financing Activities 17,037,618 5,181,435
NET CHANGE IN CASH 9,755,140 3,416,182
CASH AT BEGINNING OF PERIOD 5,122,895 2,632,413
CASH AT END OF PERIOD 14,878,035 6,048,595
CASH PAID FOR:    
Interest 513 3,116
NON CASH FINANCING ACTIVITIES:    
Reclassification of derivative liability to permanent equity   1,886,338
Financing of insurance premiums through issuance of short term notes 194,000 63,600
Conversion of preferred for common stock 50 169
Noncash exercise of options   11
Common stock issued to acquire intangible assets $ 10,180,224